Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Background Intragastric balloons (IGBs) are safe and effective in inducing weight loss in obese patients. The objective of this study was to review and analyze the available data of the effect of IGB on markers of nonalcoholic fatty liver disease (NAFLD) and liver enzymes. Methods Searches were performed of MEDLINE and Embase databases from inception through January 2016. Study inclusion criteria were the following: ≥5 overweight or obese adult patients undergoing intragastric balloon placement, with liver tests [alanine aminotransferase (ALT) or gamma-glutamyl transpeptidase (GGT)] or markers of NAFLD (e.g., imaging, biopsy) reported before balloon insertion and after balloon removal at 6 months. Results Nine observational studies and one randomized trial were identified. ALT decreased by -10.02 U/l (95 % CI, -13.2, -6.8), GGT decreased by -9.82 U/l (95 % CI, -12.9, -6.8), and BMI decreased by -4.98 kg/m(2) (-5.6, -4.4) with IGB therapy. Hepatic steatosis improved from baseline after 6 months of balloon therapy by magnetic resonance imaging (fat fraction, 16.7 ± 10.9-7.6 ± 9.8, p = 0.003), ultrasound (severe liver steatosis, 52-4 %, p Conclusion The use of intragastric balloon decreases liver enzymes and is potentially an effective short-term treatment for NAFLD as part of a multidisciplinary approach. Larger, more rigorous trials are needed to confirm the effect of IGBs on NAFLD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a reduction in NAS scores from 4 ± 2.25 to 2 ± 0.75 (p = 0.03) within six months [72].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [72]
In the citing paper
“a cohort study employing magnetic resonance elastography and liver biopsies found an 87% patient cohort experienced a median NAS reduction of three points, with 73% achieving reductions of at least two points [73].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [72]
In the citing paper
“Complementary evidence from a systematic review highlighted a significant histological improvement, demonstrating a reduction in NAS scores from 4 ± 2.25 to 2 ± 0.75 (p = 0.03) within six months [72].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [72]
In the citing paper
“studies utilizing ultrasound and MRI observed hepatic fat fraction reductions from 16.7 ± 10.9 to 7.6 ± 9.8 (p = 0.003) [72].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [72]
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
The global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Chang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
Cited by
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
“Another meta-analysis, specific for intragastric balloons, showed decrease in LFTs, steatosis and NAS six months post-surgery [201].”
BackgroundYanai, H., Adachi, H., Hakoshima, M., Iida, S., & Katsuyama, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015473 · Cited by 194
“To review and analyze the available data of the effect of intragastric balloons on markers of MASLD and liver enzymes, a meta-analysis was performed [78].”
MethodJirapinyo, P., McCarty, T. R., Dolan, R. D., Shah, R., & Thompson, C. C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.017 · Cited by 86
Self-citationJagtap, N., Kalapala, R., Katakwar, A., Sharma, M., Aslam, M., Gupta, R., Rao, P. N., Goud, R., Tandan, M., Kanakagiri, H., et al. (2021) · Indian Journal of Gastroenterology · doi:10.1007/s12664-021-01202-7 · Cited by 43
“Though more rigorous trials are needed to confirm the effects of various endoscopic interventions, they can be considered for weight loss in NAFLD if lifestyle interventions fail [37].”
BackgroundXu, L., Jiang, C. Q., Lam, T. H., Zhang, W. S., Zhu, F., Jin, Y. L., Thomas, G. N., Cheng, K. K., & Schooling, C. M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw396 · Cited by 34
“adiposity (23) or lipids (24)) were also associated with ALT, further MR studies using functionally related loci are helpful in addressing the potential issue of reverse causation (i.”
BackgroundSilva, L. B., & Neto, M. G. (2022) · Minimally Invasive Therapy & Allied Technologies · doi:10.1080/13645706.2021.1874420 · Cited by 32
“There have been reports of gastric perforations, small bowel obstructions, impaction and gastric dilatation [44].”
BackgroundManagement of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review
Hashem, A. M., Khalouf, A., & Acosta, A. J. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731704 · Cited by 34
Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Hung, C. K., & Bodenheimer, H. C. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.012 · Cited by 30
Elshaer, A., Chascsa, D. M. H., & Lizaola‐Mayo, B. (2024) · Life · doi:10.3390/life14070844 · Cited by 32
Ding, Y., Deng, Q., Yang, M., Niu, H., Wang, Z., & Xia, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s431251 · Cited by 25
“114 Additionally, a systematic study by Candlean et al revealed that 83.5% of patients’ NAS improved, while 79.2% of patients’ steatosis improved.”
BackgroundInfluentialIntragastric Balloons in Clinical Practice
Papademetriou, M., & Popov, V. (2017) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2016.12.006 · Cited by 21
Self-citationCho, J. H., Bilal, M., Kim, M. C., Cohen, J., & The Study Group for Endoscopic Bariatric and Metabolic Therapies of the Korean Society of Gastrointestinal Endoscopy (2021) · Clinical Endoscopy · doi:10.5946/ce.2020.302 · Cited by 21
“of IGB placement on the improvement of liver enzymes and NAFLD in patients with obesity.(65) Thus, IGB can be provided”
BackgroundBariatric and Metabolic Endoscopy: A New Paradigm
Telese, A., Sehgal, V., Magee, C. G., Naik, S., Alqahtani, S. A., Lovat, L. B., & Haidry, R. J. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000364 · Cited by 21
“Along with WL, other weight-independent benefits and indications for ESG (83), IGBs (44,48), and DMR are emerging including improved insulin sensitivity and improvement of liver pathology.”
BackgroundInfluentialEndoscopic Procedures for Weight Loss
Brunaldi, V., & Neto, M. G. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00450-0 · Cited by 20
Obesity: The Forgotten Pandemic
Popov, V., Aytaman, A., & Alemán, J. O. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001553 · Cited by 20
Self-citationBariatric and metabolic endoscopy: impact on obesity and related comorbidities
Mehta, A., & Sharaiha, R. Z. (2021) · Therapeutic Advances in Gastrointestinal Endoscopy · doi:10.1177/26317745211019156 · Cited by 16
Changes in resting metabolic rate and body composition due to intragastric balloon therapy
Gaździńska, A., Mojkowska, A., Zieliński, P., & Gazdzinski, S. P. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.10.011 · Cited by 15
Tasabehji, D., Saleh, S., & Mokadem, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124012 · Cited by 14
Domènech, E., Ciudin, A., Balibrea, J. M., Espinet-Coll, E., Cañete, F., Flores, L., Ferrer-Márquez, M., Turró, R., Hernández-Camba, A., Zabana, Y., et al. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2023.12.008 · Cited by 15
Silva, A. F., Bestetti, A. M., Kum, A. S. T., Nunes, B. C. M., Veras, M. D. O., Bernardo, W. M., & de Moura, E. G. H. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07453-5 · Cited by 11
“All these patients experienced spontaneous elimination of the deflated balloon, whereas other models of IGB may require endoscopic or surgical intervention [43].”
Obesity Primer for the Practicing Gastroenterologist
Jirapinyo, P., & Thompson, C. C. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001200 · Cited by 12
Self-citationLahooti, A., Johnson, K. E., & Sharaiha, R. Z. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.07.001 · Cited by 6
Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease
Cai, C. X., Carlos, S., Solaimani, P., Trivedi, B. J., Tran, C. T., & Castelino‐Prabhu, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00029-x · Cited by 6
Zou, Z., Zeng, J., Ren, T., Shi, Y., Yang, R., & Fan, J. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00183 · Cited by 7
Metabolic and Bariatric Endoscopy: A Mini-Review
Norton, B. C., Telese, A., Papaefthymiou, A., Aslam, N., Makaronidis, J., Murray, C. D., & Haidry, R. J. (2023) · Life · doi:10.3390/life13091905 · Cited by 7
“…of 5668 patients including 10 RCTs, an IGB for a maximum of six months was associated with a modest, but statistically significant, improvement in metabolic parameters, including fasting blood glucose, systolic blood pressure, HbA1c, alanine transaminase (ALT), and aspartate transaminase (AST) [91].”
BackgroundGaździńska, A., Mojkowska, A., Janewicz, M., Binder, M., Zieliński, P., & Gazdzinski, S. P. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04440-4 · Cited by 7
Gastric space-occupying devices for management of obesity and metabolic disease
Brunaldi, V., & Neto, M. G. (2020) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2020.05.001 · Cited by 3
Novel Endoscopic Bariatric Therapies for the Management of Nonalcoholic Steatohepatitis
Gala, K. S., Razzak, F. A., Rapaka, B., & Dayyeh, B. K. A. (2022) · Seminars in Liver Disease · doi:10.1055/a-1946-6285 · Cited by 2
Ghusn, W., Sridharan, M., Fromer, R., Ozdemir, M., Haff, M. G., & Vargas, E. J. (2025) · Biomedicines · doi:10.3390/biomedicines13102437 · Cited by 2
“…histologic markers of MASLD also improved, with MRI-measured hepatic fat fraction falling from 16.7 ± 10.9% to 7.6 ± 9.8% ( p = 0.003), severe steatosis on ultrasound dropping from 52% to 4% ( p 0.0001), and NAFLD activity score decreasing to 2 ± 0.75 versus 4 ± 2.25 in controls ( p = 0.03) [64].”
InfluentialSurgical Issues in NASH: Bariatric Surgery and Liver Transplantation
Paul, S., & Charlton, M. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0429-3 · Cited by 2
Acute Pancreatitis Secondary to Intragastric Balloon: A Case Report and Literature Review
Refai, F. A., Khalil, S. K., Khalil, S. K., Saeed, L., Madani, O. A., Yousif, Z. B., & Ahmed, M. I. (2023) · Cureus · doi:10.7759/cureus.45230 · Cited by 2
“IGB has been associated with different complications, including minimal abdominal pain, intractable vomiting, gastroesophageal reflux, gastric ulcers and perforation, obstruction, and the most frequent being balloon removal due to intolerance [13].”
BackgroundMandour, M. O., El-Hassan, M., Elkomi, R., & Oben, J. A. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i9.1704 · Cited by 2
Dawit, L., Quon, C. M., Bachu, V. S., Jumo, H., Micalo, L., & Issa, D. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002291 · Cited by 1
Effect of intragastric balloon on weight loss and liver elastography
Herling, A., Feiglin, S., Greener, T., Shoham, Hovel, D., Dreizin, V., Khalaila, N., Dankovich, N., Laks, S., Israeli, E., et al. (2026) · Journal of Gastrointestinal Surgery Open · doi:10.1016/j.jogsop.2026.100039 · Cited by 1
Ghazi, R., Vargas, E. J., Abboud, D. M., Razzak, F. A., Mahmoud, T., Storm, A. C., Chandrasekhara, V., & Dayyeh, B. K. A. (2022) · Journal of Digestive Endoscopy · doi:10.1055/s-0042-1754335 · Cited by 1
Flórez-Sarmiento, C., Parra-Izquierdo, V., Ordoñez, J. S. F., Valderrama, E. J., Castillo, J. D., Rodríguez, C. S., Rodríguez, V., Piñeros, M. I., & Alvarado, J. (2023) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.950 · Cited by 1
“Otras complicaciones menos frecuentes incluyen perforación gástrica, sobrellenado, obstrucción intestinal, dilatación e impactación gástrica(20).”
BackgroundFuture role for endoluminal procedures in “high-risk” bariatric patients
Brengman, M. L. (2016) · Techniques in Gastrointestinal Endoscopy · doi:10.1016/j.tgie.2016.11.004
“glucose [24,25]; and improve abnormalities in liver-associated enzymes [26,27].”
BackgroundGazdzinski, S. P., Mojkowska, A., Gaździńska, A., Gorycka, M., Zieliński, P., & Pacho, R. (2021) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2021.08.002
Gaździńska, A., Mojkowska, A., Janewicz, M., Binder, M., Zieliński, P., & Gazdzinski, S. P. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04496-2
CONDUTA CIRÚRGICA E RESULTADOS DE SAÚDE METABÓLICA APÓS CIRURGIA BARIÁTRICA: UMA REVISÃO SISTEMÁTICA
Nascimento, V. C. M., Rodrigues, M. S. D. L., Silva, I. M. P., Melo, G. C. D. S., & Gonzaga, T. C. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i6.14510
Domènech, E., Ciudin, A., Balibrea, J. M., Espinet-Coll, E., Cañete, F., Flores, L., Ferrer-Márquez, M., Turró, R., Hernández-Camba, A., Zabana, Y., et al. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2024.04.051
Papademetriou, M., Holzwanger, E. A., & Popov, V. (2024) · Springer eBooks · doi:10.1007/978-3-031-70004-0_32
Self-citationMasood, M., Sharaiha, R. Z., Siddique, A., Deal, S. B., & Kozarek, R. A. (2026) · Biomedicines · doi:10.3390/biomedicines14020345
“The histological NAS was lower after 6 months of IGB versus control with sham endoscopy and diet (2 ± 0.75 vs. 4 ± 2.25, p = 0.03) [16].”
InfluentialEndoscopic bariatric and metabolic therapies
Khurana, A. T., Nadeem, A., & Firkins, S. A. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.005
F, D. E. C. A. B. J. E.-C. E. C. F. F. L. F.-M. M. T. R. H.-C. A. Z. Y. G. A. B.-D. A. M. B. J. C. M. A. C. A. D. P.-G. A. E. L.-J. J. D. F. M. M. M. R.-M. F. S., Ciudin, A., Balibrea, J. M., Espinet-Coll, E., Cañete, F., Flores, L., Ferrer-Márquez, M., Turró, R., Hernández-Camba, A., Zabana, Y., et al. (2024) · Rovira & Virgili repository
Silva, É. R., Gonçalves, A. F. B., Souza, A. B. P. E., Donon, A. S. F., Quirino, C. C., Nascimento, G. D., de Freitas, M. M., & Santos, R. A. D. S. (2026) · Brazilian Journal of Animal and Environmental Research · doi:10.34188/bjaerv9n4-197
Metadata
- Authors
- Popov, V. B., Thompson, C. C., Kumar, N., Ciarleglio, M. M., Deng, Y., & Laine, L.
- Affiliations
- VA NY Harbor Healthcare System (US)
- Brigham and Women's Hospital (US)
- Yale University (US)
- Corresponding author
- Popov, Violeta B.
- ORCID
- Venue
- Digestive Diseases and Sciences
- Published
- 2016-05-20
- Volume
- 61
- Issue
- 9
- Pages
- 2477-2487
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2406248787
- Cited by
- 43
- References
- 54
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 3 · 2021: 12 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 2
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK34989)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- intragastric balloon, non-alcoholic fatty liver disease, liver enzymes, alanine aminotransferase, gamma-glutamyl transferase, hepatic steatosis, obesity, weight loss, NAFLD activity score
- MeSH terms
- Alanine Transaminase, gamma-Glutamyltransferase, Humans, Liver, Obesity, Ultrasonography, Weight Loss, Gastric Balloon, Treatment Outcome, Bariatric Surgery, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.